Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $2.23M, compared with -$9.22M a year earlier. Trailing-twelve-month net income was $12.01M.

Context

  • Net income amounted to 0.2% of revenue in FY2025, down 26.8 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of $108.5K (-80.4%) for the fiscal year ending Dec 2026, a slowdown from the +101.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.23M-79.8% QoQ
Last fiscal yearDec 2025
$554K+101.0% YoY
LTMMar 2026
$12.01M+126.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+124.2%+219.6%+95.4 pp
1 year+101.0%-80.4%-181.4 pp
3-year CAGR—+531.8%—
5-year CAGR+230.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
554K USD
Year-over-year change
+101.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +126.6% is the 2nd highest of 9, against a peer median of -1.4%.
  • Net income amounts to 3.8% of revenue for XERS, versus a peer median of 15.5%.
XERS Competitors
Net Income for XERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€890.37M EUR+482.2%-27.9%73.7%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$145.1M USD+80.3%+49.3%—
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$128.76M USD-3.0%-1.1%15.5%
SEPNSepterna, Inc.LTM Sep 2026$59M USD+0.3%+20.9%61.3%
GHRSGH Research PLCLTM Mar 2026$56.41M USD+34.0%+29.0%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$37.19M USD-32.9%-5.5%—
MNKDMannKind CorporationLTM Mar 2026$23.91M USD-179.4%—6.6%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.01M USD+126.6%—3.8%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$1.48M USD-67.8%-20.1%1.7%
Peer median (excluding XERS) —-1.4%-1.1%15.5%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
Deferred Income Tax(1.42M)(1.42M)(1.25M)(2.27M)0
Stock-Based Compensation11.38M12.16M10.72M18.36M22.37M
Change in Working Capital11.85M(35.15M)(6.29M)(8.82M)(10.36M)
Accounts Receivables(13.37M)(13.37M)(8.37M)(1.22M)(10.64M)
Inventory(7.47M)(7.47M)(14.8M)(8.78M)(19.29M)
Accounts Payables(4.32M)(4.32M)6.96M(9.61M)(69K)
Other Working Capital19.98M(9.99M)9.92M10.79M19.63M
Other Non-Cash Items3.5M3.52M(1.1M)(2.05M)3.91M
Operating Cash Flow(102.89M)(102.89M)(47.02M)(36.98M)28.63M
Capital Expenditures(524K)(524K)(2.26M)(868K)(696K)
Acquisitions (Net)38.47M0000
Purchases of Investments(43.02M)0(43.74M)(34.49M)0
Sales of Investments34.99M34.99M40M40.24M0
Other Investing Activities4.55M0000
Investing Cash Flow34.46M34.46M(6M)4.88M(696K)
Debt Repayment0102.72M038.17M9.17M
Common Stock Issued27M30M581K013.1M
Common Stock Repurchased(534K)(468K)(1.01M)(3.73M)(10.88M)
Dividends Paid00000
Other Financing Activities0(4.78M)(604K)1.73M0
Financing Cash Flow27.25M127.47M(1.61M)36.17M11.39M
Effect of Forex Changes(3K)(4.35M)000
Net Change in Cash59.04M59.04M(54.64M)4.07M39.32M
Free Cash Flow(103.42M)(103.42M)(49.29M)(37.85M)27.93M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.